LifeVantage Co. (NASDAQ:LFVN) Director Sells $161,200.00 in Stock

LifeVantage Co. (NASDAQ:LFVN) Director Raymond B. Greer sold 8,000 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $20.15, for a total value of $161,200.00. Following the sale, the director now owns 99,288 shares in the company, valued at approximately $2,000,653.20. This represents a 7.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

LifeVantage Trading Down 4.8 %

Shares of LFVN opened at $18.44 on Friday. LifeVantage Co. has a 12-month low of $5.22 and a 12-month high of $27.38. The company has a market cap of $231.42 million, a PE ratio of 32.93 and a beta of 0.84. The stock has a 50-day moving average price of $19.63 and a 200-day moving average price of $14.10.

LifeVantage (NASDAQ:LFVN) last announced its earnings results on Wednesday, February 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.08. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.

LifeVantage Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Monday, March 3rd will be given a $0.04 dividend. The ex-dividend date of this dividend is Monday, March 3rd. This represents a $0.16 annualized dividend and a yield of 0.87%. LifeVantage’s dividend payout ratio (DPR) is presently 28.57%.

Analysts Set New Price Targets

LFVN has been the subject of several recent analyst reports. Craig Hallum started coverage on shares of LifeVantage in a report on Tuesday, January 14th. They set a “buy” rating and a $35.00 target price on the stock. Lake Street Capital began coverage on shares of LifeVantage in a research report on Thursday, December 19th. They set a “buy” rating and a $26.00 price target for the company.

Institutional Investors Weigh In On LifeVantage

A number of large investors have recently added to or reduced their stakes in LFVN. EAM Investors LLC purchased a new position in shares of LifeVantage in the 4th quarter worth about $1,056,000. Barclays PLC lifted its position in LifeVantage by 3.6% in the 4th quarter. Barclays PLC now owns 43,472 shares of the company’s stock worth $763,000 after buying an additional 1,506 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its stake in LifeVantage by 56.2% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 93,576 shares of the company’s stock worth $1,640,000 after buying an additional 33,658 shares in the last quarter. LPL Financial LLC grew its position in LifeVantage by 301.0% during the fourth quarter. LPL Financial LLC now owns 211,039 shares of the company’s stock valued at $3,700,000 after acquiring an additional 158,405 shares during the last quarter. Finally, Hillsdale Investment Management Inc. raised its stake in shares of LifeVantage by 7.3% during the fourth quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company’s stock worth $258,000 after acquiring an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 35.32% of the company’s stock.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.